Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (3325)	4/3/2001 5:36:48 PM
From: Jibacoa	Respond to of 52153

There was a late rally on Biomira's shares today. They announced yesterday that they had closed the enrollment on the Phase III THERATOPE trial for metastatic cancer with more than 100 patients over the 900 that they had originally planned. There is a planned "Early Look" at results of the on going Phase III by the 3rd Q this year.The end-points of the trial are disease progression and survival. Their results on Phase II were statistically significant and they are now using a vaccine which is supposedly 100 times more potent. If I remember correctly, on the Phase II trial the control group had an average survival of 9 months and the treated group up to 27 months. Herceptin is reportedly effective only in about 30% of patients, wether THERATOPE's MUC-1 antigen is present in 80% of cancers. Can any Oncologist in the thread enlighten me on what is now a days the estimated average survival for metastatic breast cancer ? Biomira's Phase III started in November 1999. Could it be possible to have any statistically significant results at least on the group that started treatment more than a year ago ? I would appreciate any opinions, while I wait for some reports that may become available at the ASCO meeting in San Francisco in early May. Bernard